US 7895059

I'll search for the specific patent number and any appellate dockets, then cross-check against the authoritative full text provided.

Let me check specifically for any 2026 Federal Circuit activity and confirm the patent's current legal status.

US 7,895,059 — Verified Summary

Important scoping note: I searched specifically for 7895059 / 7,895,059. I found no 2026 Court of Appeals for the Federal Circuit docket in which US 7,895,059 is the patent in suit. Its only Federal Circuit appeal (from the PTAB invalidation) was docketed in 2017 and decided in 2018. Any 2026 Jazz/Xyrem–Xywav appellate activity that surfaced in results involves different patents (e.g., US 11,147,782; US 10,966,931; US 8,731,963) — I did not conflate them with the '059 patent. Flagging that explicitly per your "no similar numbers" instruction.

Bibliographic data (per the authoritative full text and Justia/Google Patents records)

Sources: https://patents.google.com/patent/US7895059/en ; https://patents.justia.com/patent/7895059

Note on the priority date: most sources show 2002-12-17; the Unified Patents portal snippet displays "2002-12-16." The authoritative patent text and the underlying application (10/322,348, filed 2002-12-17) support the 17th; I treat the 16th as a data artifact.

Abstract

"A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug."

Plain-language overview of the independent claims

The patent covers a closed, single-pharmacy distribution model for a sensitive/controlled drug (the specification's working example is sodium oxybate / GHB, marketed as Xyrem®), implemented through a computer that requires a single exclusive database. The six independent claims are variations on that theme:

Claim 1 — Base "exclusive central pharmacy" method (prescription drug)
Every prescription request for the drug, for every patient, must be received (in a computer processor) only at the exclusive central pharmacy, from any and all doctors permitted to prescribe it. The request carries patient-identifying data, drug data, and prescriber credentials. The information must be entered into an exclusive database tied to that pharmacy, such that all prescriptions are processed only by that pharmacy using only that database. The system then: (a) checks prescriber credentials/eligibility; (b) confirms with the patient that educational material was received/read before shipping; (c) queries the database for potential abuse; (d) mails or couriers the drug to the patient only if no potential abuse is found as to both the patient and the prescribing doctor; (e) confirms the patient received it; and (f) generates periodic reports to evaluate diversion patterns.

Claim 6 — "Exclusive control" variant
Substantively the same pipeline but framed via "authorized prescribers," with the database under the pharmacy's exclusive control, use of the database being required for distribution, and the drug being "provided" (broader than "mailed/couriered") only where the database is not indicative of potential abuse. Retains the reporting step.

Claim 9 — GHB-specific variant
Narrows the drug to gamma hydroxy butyrate (GHB): same architecture, with education confirmation required before providing GHB to the patient a first time, and database checking specifically for potential GHB abuse.

Claim 12 — GHB-specific, shipment variant
Like claim 9, but the delivery step is expressly "mailing or sending by courier GHB to the patient."

Claim 13 — GHB-specific, vertical-integration variant
Adds upstream steps: manufacturing GHB and providing the manufactured GHB only to the exclusive central pharmacy, on top of the claim-12 pipeline.

Claim 14 — "Providing" variant without reporting step
Same core as claim 6 (exclusive pharmacy, required exclusive database, credential check, education confirmation, abuse check, delivery conditioned on no abuse, receipt confirmation) but omits the "generating periodic reports" limitation. This appears to be the broadest-throttled version.

Representative dependent claims (context): claim 2 (pharmacy controls the database); claim 3 (selectively blocking shipment); claim 4 (blocking shipment where an abuse pattern is associated with the patient); claim 5 (drug = GHB); claims 7/10/15 (central pharmacy authorizes dispensing via another pharmacy); claims 8/11/16 (controls imposed at the secondary pharmacy — education confirmation, receipt confirmation, insurer contact, questioning early refills, flagging lost/stolen/destroyed/spilled or cash-paid prescriptions, supply-duration limits).

Litigation / post-grant history (directly on the '059 patent)

• IPR2015-00548 — Par Pharmaceutical, Inc. & [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) v. Jazz. Instituted July 28, 2015; Final Written Decision July 27, 2016 holding claims 1–16 unpatentable as obvious over FDA Advisory Committee ("ACA") materials.
• IPR2015-01810 (Amneal) and IPR2015-01816 (Wockhardt Bio AG) — filed Aug. 2015, joined; FWD July 27, 2016.
• IPR2015-01018 — Coalition for Affordable Drugs III LLC; institution denied Oct. 15, 2015.
• CBM2014-00149 — not instituted (procedural).
• Appeal: Jazz filed a Notice of Appeal on February 22, 2017 to the Federal Circuit (challenging the PTAB's prior-art qualification of the ACA materials, three claim constructions, and the §103 obviousness holding). The appeal was resolved in Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, Fed. Cir. (July 13, 2018), which affirmed the PTAB, invalidating the claims — the court held the ACA materials were publicly accessible printed publications and that indexing/searchability was not required.
• District court: numerous consolidated infringement actions in the District of New Jersey (including 2:11-cv-02523, 2:12-cv-06761, 2:13-cv-00391, 2:13-cv-05450, 2:13-cv-07884, 2:14-cv-04467, 2:14-cv-07757, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487, 2:18-cv-00029) and E.D.N.Y. (2:17-cv-04439).

Sources: https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2015-01810 ; https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2015-01816 ; https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2015-01018 ; Jazz Notice of Appeal (IPR2015-00548, Feb. 22, 2017); Duane Morris alert on Jazz v. Amneal (Fed. Cir. July 13, 2018): https://d3a6bds99cukeo.cloudfront.net/alerts/federal_circuit_confirms_ptab_decision_invalidating_certain_claims_xyrem_patents_0718.html

Uncertainty statements

• No 2026 CAFC docket for 7,895,059 found. Given that the patent expired (anticipated 2022-12-17) and its claims were invalidated and that invalidation affirmed in 2018, I would not expect new appellate activity on this number — but I cannot positively exclude a docket entry that is not indexed in the sources I reached. If you need a definitive PACER/CAFC check, that requires a direct docket query I cannot perform here.
• Kind code: the authoritative Google Patents record and Justia identify the grant as B2; idiyas.com's "B1" label is inconsistent with those and is likely a data error.
• Assignee chain: post-issuance assignments of record include Silicon Valley Bank (security interests, 2010/2011), Orphan Medical LLC / JPI Commercial LLC mergers and assignments (2010), Barclays (2012), Bank of America (2015), and U.S. Bank (2021). Current assignee of record is listed as Jazz Pharmaceuticals Inc.
• The '059 patent is one member of the large '730 family (including US 7,668,730; 7,765,106; 7,765,107; 7,797,171; 8,457,988; 8,589,182; 8,731,963), all sharing the 2002-12-17 priority date and all invalidated in the ACA-materials IPRs.

I'll research litigation involving US patent 7,895,059. Let me run several targeted searches.

Let me dig deeper into the specific district court cases and PTAB proceedings.

Litigation Involving U.S. Patent No. 7,895,059

Bottom line: Yes — U.S. 7,895,059 ("Sensitive drug distribution system and method," inventors Reardan, Engel, Gagne; original assignee Jazz Pharmaceuticals, Inc.; app. 12/704,097, filed Feb. 11, 2010, granted Feb. 22, 2011) has been the subject of extensive litigation. All of it flows from Jazz's Xyrem® (sodium oxybate) franchise. The assertion campaigns were Hatch‑Waxman § 271(e)(2) suits in the District of New Jersey against ANDA filers, contested at the PTAB, appealed to the Federal Circuit (the '059 claims were held unpatentable), plus follow‑on antitrust "pay‑for‑delay" class actions in which the '059 patent is one of the listed Orange Book patents.

Caveat on sourcing: I was able to complete four searches before hitting a tool limit. Everything below is grounded in the returned results; where a docket's specific defendant or patent‑in‑suit could not be confirmed from the results, I say so rather than guess. Note also that the Google Patents "family has litigation" tags list dockets associated with the family, not necessarily with the '059 patent in every instance.

1. PTAB proceedings specifically on the '059 patent

The IPR filings were part of a coordinated multi‑patent attack by Amneal/Par on seven Jazz Xyrem patents. The same real‑parties‑in‑interest dispute (Par's parents) spanned IPR2015‑00545, ‑546, ‑547, ‑548, ‑551, and ‑554 (PTAB order).

2. Federal Circuit appeal

• Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. July 13, 2018) (Nos. 2017‑1671, ‑1673, ‑1674, ‑1675, ‑1676, ‑1677, ‑2075).
  • Outcome: affirmed the PTAB's obviousness holdings invalidating the claims of U.S. 7,668,730, 7,765,106, 7,765,107, 7,895,059, 8,589,182, 8,457,988, and 8,731,963. The court upheld the Board's holding that FDA advisory‑committee materials ("ACA materials") were publicly accessible printed publications as of Oct. 4, 2001 (before the Dec. 17, 2001 critical date). (Harness IP summary; vLex opinion text)
  • Net effect: the '059 patent claims were cancelled, which is why the '059 patent shows as "Expired – Fee Related" with an anticipated expiration of 2022‑12‑17 on the Google Patents page.

3. District court Hatch‑Waxman (ANDA) litigation — D.N.J. (and one E.D.N.Y.)

Other dockets listed on the Google Patents "family has litigation" panel (associated with this patent family; I could not confirm the specific defendant/patent‑in‑suit for each from the search results): D.N.J. 2:12‑cv‑06761, 2:13‑cv‑05450, 2:17‑cv‑05487, 2:18‑cv‑00029, and E.D.N.Y. 2:17‑cv‑04439.

The general narrative of this campaign — nine infringement suits against Roxane alone, successive ¶IV notices and new Orange Book listings, and suits against Amneal, Par, Ranbaxy, Watson, Wockhardt, Lupin, Sun, and Ohm — is recounted in the antitrust complaints and Jazz's 10‑K disclosures (Jazz 10‑K excerpt; CourtListener complaint excerpt).

4. Antitrust / "pay‑for‑delay" class actions listing the '059 patent

These are not infringement suits on the '059 patent itself, but the '059 patent is expressly identified among the Orange Book patents at issue:

The Google Patents page also notes a "First worldwide family litigation" tag via DARTS‑IP and a New Jersey District Court filing at 2:14‑cv‑07757.

Litigation NOT about the '059 patent (for disambiguation)

Some search hits involve other Jazz patents and should not be attributed to the '059 patent:

• Jazz Pharmaceuticals Ireland Ltd. v. Tris Pharma, Inc., D.N.J. 2:24‑cv‑… and 2:26‑cv‑01739 — asserts the '306, '302, '494, and '446 patents (oxybate administration), not '059.
• United States ex rel. / DOJ v. Jazz Pharmaceuticals PLC, D. Mass. 1:21‑cv‑10891 — concerns the '306 patent family, not '059.
• Jazz v. Avadel (D. Del.) — concerns Lumryz/Orange Book listing, not '059.
• The '059 patent also appears as a cited reference in later patents (e.g., U.S. 9,050,302; 11,456,081), which is not litigation.

Reliability notes

• Highest confidence: IPR2015‑00548 (FWD, all claims unpatentable), IPR2015‑01018 (denied), IPR2015‑01810 and ‑01816 (joinder, terminated with the ‑548 FWD), CBM2014‑00149 (denied institution), and the Federal Circuit affirmance at 895 F.3d 1347 — all corroborated by multiple independent sources.
• Moderate confidence: the mapping of specific D.N.J. docket numbers to specific defendants other than Roxane (2:11‑cv‑02523), Amneal (2:13‑cv‑00391), Par (2:13‑cv‑07884), and Ranbaxy (2:14‑cv‑04467).
• Lower confidence / unverified: the defendants and patent‑in‑suit for dockets 2:12‑cv‑06761, 2:13‑cv‑05450, 2:14‑cv‑07757, 2:15‑cv‑05619, 2:15‑cv‑06548, 2:17‑cv‑05487, 2:18‑cv‑00029, and E.D.N.Y. 2:17‑cv‑04439. I would confirm these against PACER or Unified Patents' portal before relying on them.
• Case outcomes for the district court suits beyond the Roxane (Apr. 2017) and Par (Jan. 9, 2018) settlements — including whether any went to judgment — are not established by the results I obtained; the IPR/Federal Circuit invalidity of the '059 claims is the dispositive outcome for the patent itself.

If you want, I can attempt further targeted lookups (PACER dockets, the Unified Patents litigation portal, or the specific New Jersey complaints) to pin down the uncertain docket/defendant mappings.

I'll start by researching the PTAB proceedings that the Google Patents page flags for this patent, since the structured ODP block says none are indexed.

Now let me pin down the remaining proceedings and the appellate outcome.

I have most of the picture. Let me nail down IPR2015-01810 and confirm the claim-level dispositions in the Final Written Decisions.

PTAB / AIA Trial Proceeding Report — US 7,895,059 B2

"Sensitive drug distribution system and method" — Jazz Pharmaceuticals, Inc. (patent owner)

⚠️ Threshold flag: the ODP "no PTAB activity" block is wrong here

The structured PTAB proceedings on file block in this prompt states that the USPTO ODP API returns no AIA trial proceedings for US 7,895,059. That is not correct for this patent, and I am overriding it on the strength of (a) the Google Patents family/litigation metadata for this very patent, which lists five PTAB cases by number, and (b) multiple independent public sources (PTAB E2E document dockets, Jazz's own SEC filings, Federal Circuit opinion, PTAB bar reporting).

Five AIA trial proceedings have been filed against US 7,895,059:

Why ODP may be empty: this patent claims priority to 2002-12-17, the proceedings closed in 2016–2018, and Google Patents' own "Family has litigation" panel links these cases to Unified Patents (portal.unifiedpatents.com/ptab/case/...) and Darts-IP rather than to ODP AIA-trial datasets. Treat the ODP null result as an indexing gap, not as evidence of no PTAB history.

Proceedings overview

Total: 5 AIA trial proceedings on US 7,895,059 B2 — 3 reached Final Written Decision (all with the challenged claims held unpatentable and all appealed/consolidated into a Federal Circuit affirmance), 2 were denied institution (one IPR, one CBM). Bottom line for a defendant: this patent is dead paper. Every claim (1–16) was held unpatentable as obvious, the Federal Circuit affirmed on 2018-07-13 (Jazz Pharms., Inc. v. Amneal Pharms., LLC, No. 2017-1671), and the patent's own term expired 2022-12-17 per Google Patents. If someone is asserting US 7,895,059 against you today, the assertion is indefensible — the only live question is whether the assertion is being made in bad faith.

IPR2015-00548 — Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Filed: 2015-01-08
• Status: Final Written Decision (claims 1–16 unpatentable); rehearing denied; affirmed on appeal
• Judge panel: Jacqueline Wright Bonilla (author of the Final Written Decision), Brian P. Murphy, Jon B. Tornquist. Note: RPX and Docket Alarm metadata for the joined proceedings show a "Brian P. Murphy +4" configuration and list Susan L. C. Mitchell as an additional APJ, so the rehearing/joined-case papers may have been handled by a slightly different or expanded panel. Verify the exact roster on the FWD face page in PTAB E2E.
• Petition grounds: All 16 claims challenged. The dispositive ground was § 103(a) obviousness over the "Advisory Committee Art" ("ACA materials") — the FDA advisory-committee background materials, June 6, 2001 meeting minutes, transcript, slides, preliminary clinical safety review, briefing booklet and the Xyrem advisory-committee video transcript, all tied to the 2001-05-14 Federal Register notice (66 Fed. Reg. 24,391), plus secondary references on the Accutane, Clozaril and thalidomide restricted-distribution programs. The assertion was that Orphan Medical disclosed the claimed distribution program more than one year before the 2002-12-17 critical date.
• Institution decision: Instituted — dated 2015-07-28 (RPX and Patexia both record 2015-07-28; the Board's later oral-argument order cites "July 29, 2015" as the institution date, and the Scheduling Order is dated 2015-07-28 — treat the one-day variance as a mail/entry-date artifact). Trial was instituted on all claims 1–16, so the later SAS partial-institution problem did not touch this case. Patent Owner contested real-party-in-interest scope, and Petitioner filed a declaration (Ex. 1040, Barry Gilman, Deputy General Counsel of Par Pharmaceutical, Inc., dated 2015-05-26) stating that Par Inc. — not the Par parent holding companies — solely directed, funded and controlled both the ANDA and the IPRs. That declaration matters today for the scope of § 315(e)(2) estoppel.
• Final Written Decision: 2016-07-27 — all challenged claims (1–16) held unpatentable, including all six independent claims (1, 6, 9, 12, 13, 14) and every dependent claim. Jazz's own Form 8-K (filed 2016-07-28) states the PTAB "issued final inter partes review decisions that the claims of six patents related to the distribution system for Xyrem® … are unpatentable; as a result, these patents cannot be enforced." The Board rejected Jazz's attempt to narrow the "information identifying patients … and various credentials" element by reading in specific data fields from the specification, and construed "periodic reports" to include reports generated at irregular frequencies (not only "at regular frequencies").
• Settlement / termination: Not settled as to Par at this stage. Par later settled with Jazz on 2018-01-09, which resolved the ANDA litigation and "certain IPR proceedings currently on appeal to the Federal Circuit"; terms are confidential (Jazz granted Par a limited-volume authorized-generic right beginning 2023-07-01 and a full licence effective 2025-12-31, subject to acceleration). Jazz separately settled with Wockhardt on 2016-04-18.
• Rehearing: Patent Owner's Request for Rehearing denied 2016-12-22 (Paper 73). The Board held the request was "an attempt to reargue a position rejected in our Decision" on the construction of the "identifying" element.
• Appeal: Appeal No. 2017-1671 (Fed. Cir.), consolidated with the appeals of the five sibling REMS-patent IPRs. Decided 2018-07-13: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018) (Newman, Lourie, Reyna, JJ.; opinion by Lourie, J.). Affirmed. The opinion is publicly available at https://www.govinfo.gov/content/pkg/USCOURTS-ca13-17-01675/pdf/USCOURTS-ca13-17-01675-0.pdf (the consolidated 2017-16xx series opinion), and there is a good practitioner summary at https://ipwatchdog.com/2018/07/24/prescription-tracking-patents-confirmed-unpatentable-after-ipr-appeal/. Holdings relevant here: (i) the ACA materials were printed publications under § 102(b) — Federal Register dissemination, ≥2 months of public availability, no expectation of confidentiality, and a POSA motivated to consult the Federal Register for drug-safety notices; no indexing or searchability requirement as a per se rule; (ii) the Board correctly declined to import the "identifying information" limitation from the specification; (iii) "periodic reports" includes irregular frequencies; (iv) the Board's motivation-to-combine analysis was adequate and Jazz's reading of KSR as requiring a stated problem and a finite universe of options was wrong. The court also declined to sua sponte remand non-instituted claims/grounds under SAS.
• Defensive value: Claim 1 — and every other claim — is canceled. Any infringement theory built on US 7,895,059 is not merely weak, it is contradicted by a Federal Circuit affirmance. A demand letter citing this patent is a strong candidate for a § 285 fee motion and, if coupled with pre-suit knowledge, potentially a wrongful-assertion problem for the sender.

IPR2015-01810 — Amneal Pharmaceuticals LLC v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (filed with a Motion for Joinder to IPR2015-00548)
• Filed: 2015-08-26
• Status: Final Written Decision — joined to IPR2015-00548; decided on the 2016-07-27 FWD entered in the lead case (docket entry: "Final Written Decision IPR2015-00548")
• Judge panel: Brian P. Murphy, Jacqueline Wright Bonilla, Jon B. Tornquist, Susan L. C. Mitchell (per Docket Alarm / Patexia; the -00548 FWD metadata names Bonilla as author)
• Petition grounds: Claims 1–16 challenged on the same § 103(a) obviousness theory over the Advisory Committee Art (Ex. 1003 ACA transcript/slides, Ex. 1005 briefing booklet, Ex. 1007 Valuck declaration, plus Accutane/Clozaril/thalidomide secondary references). This was Amneal's follow-on/insurance filing after missing the January 2015 wave with Par.
• Institution decision: Instituted 2015-12-10 — "Decision Institution of Inter Partes Review and Grant of Motion for Joinder." By joining, Amneal accepted the existing trial schedule and the lead-case record rather than running a parallel case.
• Final Written Decision: The 2016-07-27 FWD in IPR2015-00548 controls; all of claims 1–16 were held unpatentable. Amneal remained a party through the Federal Circuit appeal (the 2018 affirmance is captioned Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 2017-1671).
• Settlement / termination: No settlement at the PTAB stage; Amneal was still adverse to Jazz in the consolidated New Jersey ANDA litigation when the appeal was decided.
• Appeal: Included in the consolidated appeal No. 2017-1671; affirmed 2018-07-13.
• Defensive value: Amneal's joinder means Amneal (and its privies) are squarely within the § 315(e)(2) estoppel that attached in IPR2015-00548 as to claims 1–16. For a defendant unrelated to Amneal, this case is useful persuasive precedent on the ACA-materials prior-art theory but adds no separate estoppel.

IPR2015-01816 — Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (joined to IPR2015-00548)
• Filed: 2015-08-27
• Status: Indexed in Google Patents, RPX, Patexia and DrugPatentWatch as "Final Written Decision" with a decision date of 2016-07-27. Conflict to flag and verify: Jazz's own SEC filings state that after the 2016-04-18 Wockhardt settlement, "the U.S. Borrower and Wockhardt filed a joint motion to terminate the IPR petitions filed or joined by Wockhardt which the PTAB subsequently granted." Those two statements are in tension (a granted termination in April/May 2016 is inconsistent with a merits FWD in July 2016 unless the metadata is mirroring the lead-case FWD date). Do not represent the precise disposition of the Wockhardt record without pulling the docket in PTAB E2E.
• Judge panel: Brian P. Murphy, Jacqueline Wright Bonilla, Susan L. C. Mitchell (a metadata field attributes the FWD writing to Murphy — again likely a mirroring artifact of the joined-case entry)
• Petition grounds: Claims 1–16, the same ACA-materials § 103(a) theory (see IPR2015-01810 exhibit list, which is the same set).
• Institution decision: 2015-10-30 (RPX / Patexia / DrugPatentWatch), with joinder to IPR2015-00548. The Board's 2016-03-30 oral-argument order confirms IPR2015-01810 and IPR2015-01816 (among others: -01813, -01814, -01815, -01817, -01818, -01820) were joined to the lead IPRs.
• Settlement / termination: Jazz–Wockhardt settlement 2016-04-18; terms confidential; Jazz granted Wockhardt a licence to market generic sodium oxybate on or after 2025-12-31, or earlier on certain events. (Note: the HBSS class-action complaint dates this settlement 2016-04-28; Jazz's SEC filing says 2016-04-18. Use the SEC date, but be aware of the variance.)
• Appeal: Not appealed by Wockhardt; Duane Morris's client alert confirms Wockhardt "settled its case prior to the Federal Circuit decision."
• Defensive value: Low independent value. It is a joinder to the same prior-art theory that killed the patent, and it illustrates the settlement-driven exit pattern that removed the second-wave petitioners from the appeal.

IPR2015-01018 — Coalition for Affordable Drugs III LLC v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review
• Filed: 2015-04-06
• Status: "Not Instituted – Procedural" (Google Patents verbatim) → plain English: the Board denied institution; no trial, no FWD, no appealable merits ruling.
• Judge panel: Jacqueline Wright Bonilla, Susan L. C. Mitchell, Brian P. Murphy (Paper 17, Decision Denying Institution of Inter Partes Review, 2015-10-15)
• Petition grounds: § 103 obviousness over the Drug Advisory Committee ("DAC") Transcript and Clinical Study Report combined with the Lilly and Camarda references.
• Institution decision: Denied 2015-10-15. The panel gave four reasons: (1) Patent Owner's real-party-in-interest challenge failed — the record did not show that any unnamed Hayman-fund investor "could have exerted control over the filing of the Petition"; (2) the Board declined to deny under §§ 314(a)/315(b) on "improper purpose" grounds, holding that "[p]rofit is at the heart of seeking patent protection in almost all inter partes reviews" and "an economic motive for challenging a patent claim alone does not raise abuse of process issues"; (3) Petitioner failed to show the DAC Transcript was publicly available as of 2001-06-27 (the Federal Register notice's "generally posted about 3 weeks after the meeting" language, plus a Wayback Machine exhibit showing non-availability, was insufficient); and (4) even reaching the merits, Petitioner "glosses over the differences between the DAC Transcript and Lilly or Camarda" and gave no reason why a POSA would "cobble together disclosures from the[se] disparate references."
• Settlement / termination: None (institution denied).
• Appeal: None — denial of institution is not appealable (§ 314(d)).
• Defensive value: Two takeaways. First, this is the footnote that proves the patent owner did fight and win sometimes — but note it won on the prior-art status of a single transcript, not on the merits of the claims. Second, this is the Kyle Bass / Hayman Capital "Coalition for Affordable Drugs" campaign: a hedge-fund-funded, short-selling-motivated petitioner. If a defendant today is looking at who has already tried, the answer includes a defensive aggregator figure (Unified Patents is the metadata source for the family's litigation links) plus the Bass funds. Coverage: https://natlawreview.com/article/coalition-affordable-drugs-iii-v-jazz-pharms-denying-institution-although-petitioner

CBM2014-00149 — Par Pharmaceutical, Inc., Roxane Laboratories, Inc., and Amneal Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.

• Type: Covered Business Method review (AIA § 18; 35 U.S.C. § 321)
• Filed: 2014-06-24
• Status: "Not Instituted – Procedural" (Google Patents verbatim) → institution denied; no trial.
• Judge panel: Brian P. Murphy, APJ (the decision was entered in four related CBMs — CBM2014-00149 against the '059 patent, plus -00150 ('988), -00151 ('730) and -00153 ('182))
• Petition grounds: Claims 1–16 of the '059 patent challenged under 35 U.S.C. §§ 101 (Alice/abstract idea), 102(b), and 103(a). This was the first attempt by generic drug makers to attack Orange Book–listed patents through CBM review.
• Institution decision: Denied 2015-01-13 (Paper 12). The Board held the '059 patent is not a "covered business method patent" because it does not claim "a method or corresponding apparatus for performing data processing or other operations used in the practice, administration, or management of a financial product or service." Focusing "firmly on the claims," the panel found the claims recite "checks" ("checking") and "controls" ("confirming") on "shipping," "mailing," or "providing" a prescription drug to prevent abuse and diversion — not an activity involving the movement of money or extension of credit. The Board rejected the "used in commerce" theory as an improper expansion of CBM scope, and rejected the argument that PTO Class 705 classification or examiner-cited billing prior art made the patent CBM-eligible. Decision PDF: https://ptabtrialblog.com/wp-content/uploads/2015/01/CBM2014-00149-150-151-153-Denying-Institution-of-Cover-Business-Method-Review-20150113.pdf
• Settlement / termination: None.
• Appeal: None.
• Defensive value: Forecloses the § 101 / Alice route at the PTAB for patents of this shape — a CBM petition today against a drug-distribution patent of this kind will fail for the same jurisdictional reason. Any § 101 challenge must be brought in district court.

Strategic summary

Which claims are canceled vs. sustained vs. untested. There is no "surviving claim" to build a case on. Claims 1–16 — the entire patent — were held unpatentable as obvious in IPR2015-00548 (FWD 2016-07-27), a holding in which the joined Amneal (IPR2015-01810) and Wockhardt (IPR2015-01816) proceedings participated, and which the Federal Circuit affirmed on 2018-07-13 in Jazz Pharms., Inc. v. Amneal Pharms., LLC, No. 2017-1671. No claim of the '059 patent was sustained, and no claim went untested — the petitioner challenged claims 1 through 16 in the IPR and the Board instituted on all of them. The only claims that were never adjudicated on the merits are those in the denied petitions: the CBM2014-00149 claims (all 16) and the IPR2015-01018 claims, both killed at the institution threshold for jurisdictional/evidentiary reasons rather than merits. On top of the invalidity finding, the patent's term expired 2022-12-17 (anticipated expiration, per Google Patents; legal status "Expired – Fee Related"/"Expired – Fee Related" with a 2022-12-17 anticipated expiration entry), so there is no injunction exposure and no live royalty tail on this particular patent.

Estoppel landscape. § 315(e)(2) now bars Par Pharmaceutical, Inc., Amneal Pharmaceuticals LLC, Wockhardt Bio AG, and their privies/RPIs from asserting in district court any ground they raised or reasonably could have raised in IPR2015-00548 and its joined proceedings — and because all 16 claims were in the IPR, that estoppel is effectively patent-wide as to those parties. A defendant not in privity with those petitioners is not estopped, but that cuts the other way for the patent owner: a fresh defendant is free to run the same ACA-materials § 103 theory, and the Federal Circuit has already blessed the key prior-art predicate (FDA advisory-committee materials are printed publications; no indexing required). Practically, the estoppel question is moot because the claims are gone; the useful estoppel residue is defensive against Jazz and its successors-in-interest asserting later REMS patents against the same conduct.

Pattern signals. (1) Amneal is a repeat filer — the January 2015 wave (IPR2015-00545/-546/-547/-548/-551/-554, covering the '182, '106, '107, '059, '988 and '730 patents) plus IPR2015-01810 here and the separate IPR2015-01903 against US 8,731,963. Par co-filed the first wave and was a named petitioner in IPR2015-00548. Wockhardt filed a second-wave petition and joined. So the entire Xyrem generic cohort coordinated. (2) The patent owner fought hard and lost — Jazz requested rehearing (denied 2016-12-22), appealed all seven REMS-patent decisions, and lost across the board in a single precedential-style opinion. (3) Defensive aggregator presence: the Google Patents family metadata sources the PTAB/litigation history from Unified Patents and Darts-IP, and the family has an extraordinarily long assertion history across D.N.J. and E.D.N.Y. (case numbers 2:10-cv-06108, 2:11-cv-02523, 2:12-cv-06761, 2:13-cv-00391, 2:13-cv-05450, 2:13-cv-07884, 2:14-cv-04467, 2:14-cv-07757, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487, 2:17-cv-04439, 2:18-cv-00029). The settlement wave (Wockhardt 2016-04-18, Ranbaxy 2016-05-09, Teva 2018-03-30, Par 2018-01-09, plus the first filer West-Ward/Hikma) all featured confidential terms with entry dates of 2023-07-01 and 2025-12-31 — i.e., the invalidity exposure was neutralized commercially, not legally.

Recommended next steps

1. If you have a demand letter asserting US 7,895,059 — say the patent is dead, with citations. Cite the FWD disposition (claims 1–16 unpatentable, 2016-07-27, IPR2015-00548) and the affirmance: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 2017-1671 (Fed. Cir. July 13, 2018), slip opinion at https://www.govinfo.gov/content/pkg/USCOURTS-ca13-17-01675/pdf/USCOURTS-ca13-17-01675-0.pdf. Also pull the certificate confirming cancellation of claims 1–16 from the USPTO PatentCenter document history (link available from the Google Patents "USPTO PatentCenter" link on the patent page) — the FWD plus the appellate mandate is what formally extinguishes the claims. Then assess § 285 / Rule 11 exposure for the sender.
2. Do not waste a filing on an IPR or CBM against the '059 patent. The patent expired 2022-12-17, all claims were held unpatentable and affirmed, and a CBM petition of this shape will fail on the § 18(d)(1) jurisdictional ground that killed CBM2014-00149. There is no active proceeding here, so there is no institution-deadline, oral-hearing, or statutory one-year FWD milestone to track.
3. Redirect the analysis to the rest of the family — that is where the live risk is. Jazz's REMS portfolio is not limited to the invalidated patents. Google Patents' "Cited By" list shows Jazz continues to prosecute and publish in this space, including US 11,456,081 B1, "Sensitive drug distribution systems and methods" (priority 2017-07-20, Jazz Pharmaceuticals, Inc.), and the family shows US 7,797,171 B2 still "Active" with a projected term into 2026-07-19 (per the Google Patents family table). If you are facing a current Xyrem-REMS or sodium-oxybate distribution assertion, identify the actual asserted patent number before conceding anything — and note that the '963 patent's exposed claims were limited to claims 24, 26 and 27 (25 of 28 claims were never instituted), so any later-family patent must be analyzed on its own claims, not on the '059 outcome.
4. Verify two record items in PTAB E2E before relying on them in a brief (I could not resolve them from public aggregators and will not guess): (a) the precise disposition of IPR2015-01816 — merits FWD versus termination following the 2016-04-18 Wockhardt settlement; and (b) the exact APJ roster on the IPR2015-00548 FWD versus the rehearing paper (some sources show a four- or five-judge configuration including Susan L. C. Mitchell). Both are checkable at the PTAB E2E public docket (https://ptacts.uspto.gov/ptacts/) and via the Google Patents case links for this patent (portal.unifiedpatents.com/ptab/case/IPR2015-00548, .../IPR2015-01810, .../IPR2015-01816, .../IPR2015-01018, .../CBM2014-00149).

I'll research the assignment record for US 7,895,059, starting with the USPTO Assignment Center and cross-referencing the legal-events data in the authoritative text.

Let me search for the specific assignment records and reel/frame data.

Let me look for the recorded reel/frame data and any assignment abstract of title for this patent.

Data-provenance note (read first)

I could reconstruct the events in the chain from the authoritative full text's legal-events record (Google Patents, mirrored from USPTO assignment data) and from SEC/PTAB/court records. I could not retrieve reel/frame numbers or correspondent-of-record names for US 7,895,059 through the tools available in this session — the Assignment Center's record-level detail (which is where reel/frame and correspondent live) was not reachable, and no indexed third-party page reproduced the Abstract of Title for this patent. Per your "don't fabricate" constraint, every reel/frame and correspondent field below is marked "not retrieved" rather than guessed. The one reel/frame I did see in search results (MERGER, reel 3224/0016, recorded 2006-01-10, per a TTAB record in case 92059193) is a plausible match to the Jazz/Orphan Medical merger but I could not confirm it attaches to this patent — treat it as an unverified lead only, not a finding.

Inventors

Caveat / honesty flag: the authoritative patent front page lists only Jazz Pharmaceuticals as assignee, because the "original assignee" field reflects the recorded owner, not the filer. The underlying application (Ser. No. 10/322,348, filed 2002-12-17) predates the Jazz/Orphan merger. All three inventors are Minnesota residents, Orphan Medical, Inc. was headquartered in Minnetonka, MN, and the specification describes Orphan's own Xyrem restricted-distribution program (FDA approval July 17, 2002). Investor-side complaints in the Xyrem antitrust MDL state that "at first Orphan Medical and later Jazz, filed for and obtained" the '730-family patents. That is strong circumstantial support for Orphan Medical as the filing-time employer — but I did not see a recorded assignment naming Orphan Medical as assignor of Ser. No. 10/322,348 in the data I could reach, so I mark the employer column as inference, not confirmed record.

Unusual patterns: All three inventors are co-located in one metro and all appear on the single 2002 priority filing; there is no evidence in the record I reached of inventors spinning out, forming a separate company, or transferring to a successor entity. I could not verify whether any inventor left Orphan Medical within 12 months of filing — that requires personnel records I cannot access. No fire-sale precursor signal is supported by the data I have.

Contradiction flag vs. previous section: the earlier summary states "Original assignee: Jazz Pharmaceuticals, Inc." That is correct for the patent as issued but should be read with the refinement above — the applicant/owner at filing (2002) was Orphan Medical, Inc., with Jazz succeeding by merger.

Original assignee

Two layers must be separated:

• On the face of US 7,895,059 (issued 2011): Jazz Pharmaceuticals, Inc. (Palo Alto, CA) — a consequence of the 2005 merger, not the 2002 filer.
• Original filer of the priority application (2002): Orphan Medical, Inc. (Nasdaq: ORPH), Minnetonka, MN — a specialty pharmaceutical company whose products were Xyrem® (sodium oxybate), Antizol®, and Cystadane®.

Did they ship a product embodying the claims? Yes. Xyrem is the working example throughout the specification, and the claimed method is essentially a description of the restricted-distribution/REMS program under which Xyrem was actually dispensed — a single exclusive central pharmacy, a central patient/prescriber registry/database, prescriber credential checks, patient education confirmation before first shipment, receipt confirmation, and diversion-pattern reporting. Xyrem was approved by FDA on July 17, 2002 and launched by Orphan Medical; the claimed model was commercially implemented.

Primary line of business: specialty/orphan pharmaceuticals (CNS — narcolepsy/cataplexy — and later oncology).

Current status:

• Orphan Medical, Inc. — acquired by Jazz Pharmaceuticals, Inc. via a cash merger announced 2005-04-19 ($10.75/share, ~$125–150M), closing in 2005; became a wholly owned subsidiary, then in 2010 was reorganized into Orphan Medical, LLC and JPI Commercial, LLC before title was consolidated back into Jazz Pharmaceuticals, Inc. Orphan Medical as such no longer exists as an independent filer.
• Jazz Pharmaceuticals — operating, not acquired, never bankrupt. IPO on Nasdaq June 1, 2007 (JAZZ); today Jazz Pharmaceuticals plc, HQ Dublin, Ireland; Xyrem/Xywav franchise plus Epidiolex, Zepzelca, Rylaze, Ziihera; ~$4B revenue scale. Note the regulatory blemish on the Orphan Medical-era marketing of Xyrem (2007 guilty plea / ~$20M False Claims Act + criminal settlement) — relevant context, not an ownership event.

Assignment timeline

Chronological, drawn from the authoritative legal-events record. Reel/frame and correspondent: not retrieved for every entry (see provenance note).

Pattern note on #2–#7: the identical Merger → Orphan Medical LLC → JPI Commercial LLC → Jazz Pharmaceuticals Inc. sequence appears twice (2010-11-12/11-17 and 2010-11-26/12-22). The most likely explanation is two recordings covering different application/patent numbers within the '730 family (or a re-recording), not two economically distinct transfers. The net effect is a round trip that leaves title exactly where it started — in Jazz Pharmaceuticals, Inc. That is the signature of a tax/structure reorganization, not a disposition.

Corporate history not captured in the per-patent record but necessary context (from SEC/PTAB/court sources): Jazz Pharmaceuticals, Inc. → Jazz Pharmaceuticals plc (2012 Irish inversion); EUSA Pharma acquisition (2012); Orphan Medical merger (2005).

Timeline diagram

timeline
    title Ownership of US 7895059
    2002 : Priority application filed
    2005 : Jazz acquires Orphan Medical
    2010 : Continuation application filed
         : Merger into Orphan Medical LLC
         : Assignment to JPI Commercial LLC
         : Assignment to Jazz Pharmaceuticals Inc
    2011 : Patent issues
         : Jazz sues generics in New Jersey
    2012 : Barclays security interest
    2015 : BofA security agreement
    2016 : Claims invalidated in IPR
    2018 : Federal Circuit affirms
    2021 : US Bank security agreement
    2022 : Patent expires

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
Orphan Medical, LLC and JPI Commercial, LLC are Jazz-family entities, and the chain returns title to Jazz Pharmaceuticals, Inc. (recorded 2010-11-17 / 2010-12-22). A shell-entity transfer requires the patent to move out of the operating company to a licensing-only vehicle; here it moved within the corporate family and back to the parent. No evidence of a "IP/Patents/Licensing/Holdings/Ventures" assignee, no registered-agent-service address surfaced, and no products-absence finding (Jazz ships Xyrem). Call: not present.

2. Known asserter in the chain — NOT PRESENT.
No assignee at any point matches a public NPE roster. Across the chain the assignees are Jazz Pharmaceuticals, Inc. / affiliated Jazz entities, plus secured lenders (Silicon Valley Bank, Barclays Bank PLC, Bank of America, N.A., U.S. Bank National Association). None of Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, or Spangenberg entities appears. Unified Patents and RPX both index Jazz as the patent owner/defendant-side operating company, not as an asserter on their NPE lists. Call: not present.

3. Repeat correspondent across the chain — UNKNOWN / NOT ASSESSABLE.
This is the strongest of your tells and I could not test it: no correspondent name or firm was retrievable for any of the 14 recorded events. I will not infer one. Action item: pull the Abstract of Title at https://assignmentcenter.uspto.gov/ (search patent 7,895,059) and compare the correspondent on reel entries covering 2010-11-12 through 2010-12-22. Expectation, flagged as expectation only: because the 2010 recordings are Jazz corporate-counsel work product, the correspondent is likely Jazz's regular IP counsel — not an NPE filing shop. Call: unclear.

4. Cascading transfers — PRESENT IN FORM, BUT NOT AN NPE CASCADE.
Six recorded events land in a ~6-week window (2010-11-12 → 2010-12-22) with chained LLCs, which literally satisfies the pattern. But the discriminating tells are absent: the LLCs are not unrelated shells, there is no arms-length consideration, and the chain terminates back at the same parent. Two recordings of the same sequence further indicate family-wide re-recording rather than a genuine multi-hop cascade. Call: flag as partial/warrants-a-look, with concrete contrary evidence.

5. Pre-litigation transfer — PRESENT IN TIMING, BUT INVERTED IN SUBSTANCE.
The 2010-11/12 recordings do fall within roughly six months of the earliest New Jersey infringement case on the '730 family (2:11-cv-02523), and title was deliberately consolidated into Jazz Pharmaceuticals, Inc. — which is the plaintiff. In a true pre-litigation NPE transfer, title moves away from the operating company to an assertion vehicle to set venue/standing. Here it moved to the operating-company plaintiff. Call: timing matches; purpose is the opposite of the NPE tell. Also note I could not confirm that 2:11-cv-02523 specifically named the '059 patent (it issued 2011-02-22).

6. Bankruptcy fire-sale — NOT PRESENT.
No Chapter 7/11 anywhere in the chain. Jazz IPO'd June 1, 2007 and has been a going concern since; Orphan Medical was acquired at a premium, not liquidated. No §363 sale, no stalking-horse, no Kodak/Nortel/Polaroid-style auction. The only court events are PTAB IPRs and Hatch-Waxman ANDA suits, which are ordinary operating-pharma patent enforcement, not insolvency. Call: not present.

7. Privateering — NOT PRESENT.
Jazz asserts in its own name as operating-company plaintiff (e.g., Jazz v. Roxane, D.N.J. 2:10-cv-06108; the consolidated New Jersey ANDA cases; Jazz v. Avadel). There is no NPE entity asserting on Jazz's behalf. SEC filings show Jazz holding and defending its own portfolio. The inverse of privateering is what's documented: an operating company enforcing its own patents against direct competitors. Call: not present.

8. Defensive aggregator — NOT PRESENT.
The chain ends at Jazz Pharmaceuticals, Inc. (per the current assignee-of-record listing), an operating company. No RPX, AST, LOT Network, Unified Patents, or OIN step anywhere. The patent has not been neutralized by aggregation — it was neutralized by adjudication: claims 1–16 held unpatentable in IPR2015-00548 (FWD 2016-07-27), joinders in IPR2015-01810 and IPR2015-01816, affirmed in Jazz Pharmaceuticals, Inc. v. [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) (Fed. Cir. 2018), and it expired (fee-related) with anticipated expiration 2022-12-17. Call: not present.

Verdict

Operating-company assertion.

The assignment record shows one operating company and its secured lenders, nothing else: an intra-family reorganization (Orphan Medical, Inc. → Orphan Medical, LLC → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc., recorded 2010-11-12 through 2010-12-22) that returns title to the same parent, bracketed by ordinary venture-debt/lender security agreements with Silicon Valley Bank (2010-06-30, 2011-04-11), Barclays Bank PLC as collateral agent (2012-08-06), Bank of America, N.A. (2015-06-19), and U.S. Bank National Association (2021-05-05), each with matching releases. Every one of the eight NPE signals is either not present or, in the two cases where the form matches (rapid 2010 recordings; proximity to the 2011 New Jersey suits), the concrete evidence points the other way — title moved to the operating-company plaintiff, and the LLCs are Jazz affiliates, not shell asserters. Jazz Pharmaceuticals ships Xyrem (the specification's working example) and litigates in its own name against generic competitors; the record contains no transfer to any NPE-roster entity.

Two important qualifications: (a) the absence of reel/frame and correspondent data means signal #3, your strongest tell, remains untested here — this is a limitation of my sources, not a negative finding; (b) the patent is expired (2022-12-17) and its claims were invalidated and that invalidation affirmed (2018), so there is no live assertion to characterize regardless of ownership.

Verify at: https://assignmentcenter.uspto.gov/ (search patent number 7,895,059; note the original 2002 assignment of Ser. No. 10/322,348 to Orphan Medical, Inc. may sit on a separate reel that predates this continuation's record set).

I'll gather the complete citation list for US 7,895,059 and cross-check the authoritative text provided.

I have the citation universe. Let me verify key reference details (dates, content) for the most relevant patent citations.

Prior-Art Analysis — US 7,895,059 B2

"Sensitive drug distribution system and method"

Scoping confirmation: I searched on the literal string 7895059 / 7,895,059. The record resolves uniquely to US 7,895,059 B2 (Appl. No. 12/704,097, filed 2010‑02‑11, a continuation of Ser. No. 10/322,348 filed 2002‑12‑17, granted 2011‑02‑22, Jazz Pharmaceuticals, Inc.). I did not substitute any similar number (e.g., US 7,895,059 is distinct from the sibling patents 7,668,730 / 7,765,106 / 7,765,107 / 7,797,171 / 8,457,988 / 8,589,182 / 8,731,963, which are separate members of the same family). Consistent with the earlier section, the grant kind‑code is B2.

0. Methodological caveats you should read first

1. Two evidentiary buckets. US 7,895,059 carries both (a) a References Cited list of U.S. patents and pre‑grant publications (43 items on the face of the patent; Unified Patents indexes 56 "Patent Art" items), and (b) a body of non‑patent literature (NPL) cited of record. The NPL is the art that actually killed the claims (see §5) — so it is the "most relevant prior art" in the adjudicated sense.

2. Critical date = December 17, 2002 (pre‑AIA). For true §102(b) art, the reference must be published/patented more than one year before filing, i.e., before December 17, 2001 (since the operative filing chain runs to 2002‑12‑17). References dated after that but filed before the invention date can only be §102(e) art.

3. §102 vs. §103 — candid assessment. Every independent claim (1, 6, 9, 12, 13, 14) contains the twin limitations "only at the exclusive central pharmacy" and "exclusive computer database … processed only by the exclusive central pharmacy using only the exclusive computer database." No cited patent reference, standing alone, discloses that combined single‑pharmacy/single‑database architecture. Accordingly, none of the patent citations below is a clean single‑reference §102 anticipator of the independent claims as written. Their real role is as §103 combination art (and, for a few, as §102 anticipation of narrower sub‑concepts). I map this explicitly in §4.

4. I did not individually verify the full disclosure text of every one of the 43/56 references — descriptions below are drawn from the patent's own face, Google Patents, Justia, and the litigation record I could retrieve, and I flag where I am relying on title/abstract only. Where I could not verify a title, I say so rather than guess.

1. Restricted‑distribution / patient risk‑management references — highest relevance

These are the closest patent art because they disclose gating dispensing on registration, education, and eligibility checks.

Note the family relationship: these Celgene references are the "prior art" the '059 patent's own specification implicitly distinguishes (the '501 patent is expressly discussed), which is why they recur in the family's prosecution.

2. Controlled‑substance / pharmaceutical tracking, dispensing & inventory references

3. Computerized prescribing, pharmacy‑management and e‑Rx references

(Dates for the six‑series items 6,347,329 / 6,564,121 / 6,687,676 / 6,755,784 / 6,952,681 / 7,058,584 are taken from the face of the sibling U.S. 7,765,106, which lists them in that order with dates 2/2002, 5/2003, 2/2004, 6/2004, 10/2005, 6/2006.)

4. Antecedent dispensing/hardware and packaging references (low relevance)

5. U.S. pre‑grant publications listed of record — §102(e) screening required

The '059 patent's citation list also includes numerous U.S. published applications. Caution: those with publication dates after 2002‑12‑17 are only prior art under §102(e) (i.e., if their underlying U.S. filings predate the critical date). Examples from the of‑record list (titles/dates as indexed):

• US 2001/0042050 A1 (Fletcher et al., Nov 2001); US 2001/0047281 A1 (Keresman III et al., Nov 2001); US 2002/0010661 A1 (Waddington et al., Jan 2002); US 2002/0032581 A1 (Reitberg, Mar 2002); US 2002/0032582 A1 (Feeney, Jr. et al., Mar 2002); US 2002/0042725 A1 (Mayaud, Apr 2002); US 2002/0042762 A1 (McQuade et al., Apr 2002); US 2002/0052762 A1 (Kobylevsky et al., May 2002); US 2002/0161607 A1 (Subich, Oct 2002); US 2002/0177232 A1 (Melker et al., Nov 2002) — these fall at/around the critical date and warrant individual §102(e)/(b) screening.
• 2003/0033168, 2003/0046110, 2003/0050802, 2003/0093295, 2003/0110060, 2003/0127508, 2003/0144876, 2003/0160698, 2003/0197366, 2003/0229519, 2003/0233256, 2004/0008123, 2004/0019567, 2004/0019794, 2004/0078237, 2004/0107117, 2004/0117126, 2004/0122712, 2004/0122713, 2004/0162740, 2004/0176985 — published well after the critical date; prior art only if their underlying U.S. filings antedate 2002‑12‑17. Unified Patents ties several to assignees including PDX Inc. (2004/0122713, "System and Method for Prescription Home Delivery," priority 2002‑12‑19), Medco (2003/0144876), IBM (2004/0019567), Battelle (2004/0008123), Medvantx (2002/0032582), PacifiCare (2003/0050802), PRN Technologies (2004/0078237), Interchange Medical (2004/0019794).

Not prior art: US 2005/0216309 A1 and US 2005/0222874 A1 (both Reardan et al.) are the applicant's own family publications — they are the pre‑grant publications of the later family continuations and cannot be prior art against the '059 patent.

6. The art that actually decided the case — Non‑Patent Literature (decisive)

Under §102(b) and applied in §103, the operative prior art was a body of NPL referred to in the IPRs as the "ACA Materials." These are the most relevant prior art in the practical sense, and they are what the Federal Circuit held to be printed publications:

The PTAB held claims 1–16 unpatentable as obvious over the ACA Materials (IPR2015‑00548, FWD Jul. 27, 2016; joined with IPR2015‑01810/‑01816), and the Federal Circuit affirmed in Jazz Pharms., Inc. v. Amneal Pharms., LLC (Fed. Cir. Jul. 13, 2018), holding the ACA materials were publicly accessible printed publications and that indexing was not required.

Claim mapping (as adjudicated): the ACA Materials were applied against all of claims 1–16 — i.e., every independent claim (1, 6, 9, 12, 13, 14) and every dependent claim (2, 3, 4, 5, 7, 8, 10, 11, 15, 16) — under §103, not single‑reference §102. The court additionally addressed Jazz's claim‑construction arguments on "periodic reports" (holdings that irregular‑frequency reports were covered) and "information identifying."

Other NPL of record (from the patent's "Other Publications," also usable as §102(b)/§103 art):

• "Diversion Prevention Through Responsible Distribution," NADDI Regional Training (May 2001, 12 pp.); NADDI Regional Training Tennessee (Jun. 2001, 14 pp.); NADDI National Conference (Nov. 2001, 15 pp.).
• "System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) Starter Kit," Celgene Corp. (2001), 103 pp. — the thalidomide restricted‑distribution program.
• Ukens, C., "Specialty Pharmacy," Drug Topics, 144 (Jun. 5, 2000), 40–47.
• "An Interview with Orphan Medical about Xyrem," talkaboutaleep.com (Feb. 12, 2001), 3 pp.
• NASCSA National Conference (Nov. 2000), 8 pp.

7. Bottom line — the "most relevant" prior art, ranked

1. FDA Advisory Committee Materials (ACA), June 2001 — NPL, §102(b) — the only art that was found to invalidate all 16 claims (via §103). Most relevant, full stop.
2. US 6,315,720 B1 — Celgene — §102(b) — closest patent reference; discloses registration/eligibility gating and approval‑code dispensing (claims 1, 6, 14 sub‑steps).
3. US 6,045,501 A — Celgene — §102(b) — same platform (prescriber/pharmacy/patient registration) — claims 1, 6, 14.
4. US 6,755,784 B2 — Celgene — §102(e) — restricted‑access delivery — claims 1, 6, 14.
5. US 6,952,681 B2 (Data Reduction Systems) — §102(e) — controlled‑substance distribution tracking → the "periodic reports / diversion patterns" step (claims 1, 6, 9, 12, 13).
6. US 6,055,507 A (Cunningham) and US 6,112,182 A (Akers) — §102(b) — dispensing/tracking and integrated pharmacy management → claims 1/6 sub‑steps.
7. US 5,845,255 A / US 5,737,539 A / US 5,924,074 A — §102(b) — electronic prescribing & records → the "receiving … in a computer processor" and database‑field elements.

No cited patent reference anticipates claims 1, 6, 9, 12, 13 or 14 on its own, because none discloses the "only at the exclusive central pharmacy / exclusive computer database" architecture. That limitation is the reason the claims survived examination (over the patent art of record) yet still fell at the PTAB over the NPL — an important asymmetry for any validity or clearance analysis.

8. Uncertainty / verification flags

• US 6,347,329, 6,564,121, 6,687,676 — I could not verify titles/subject matter from the sources retrieved; I deliberately left them unmapped rather than guess.
• Reference‑type assignments (which citations are examiner‑cited vs. applicant‑cited, and which are §102(a) vs. §102(b)) were not fully resolvable from the truncated citation block; the §102 category shown is my classification based on dates, not a verified PTO label.
• Priority date: the authoritative patent text and the parent application (10/322,348, filed 2002‑12‑17) support 2002‑12‑17; a Unified Patents snippet shows "2002‑12‑16," which I treat as a data artifact (consistent with the earlier section).
• I found no 2026 Federal Circuit activity naming 7,895,059 as the patent in suit; its invalidation was affirmed in 2018.

Sources: https://patents.google.com/patent/US7895059/en ; https://patents.justia.com/patent/7895059 ; https://portal.unifiedpatents.com/patents/patent/US-7895059-B2 ; IPR2015‑00548 petition/Notice‑of‑Appeal record (ptacts.uspto.gov) and Petitioner exhibit lists (docketalarm/paragraphfour); Jazz Pharms., Inc. v. Amneal Pharms., LLC, Fed. Cir. (Jul. 13, 2018) via Mondaq/McDermott and Knobbe Martens summaries; DrugPatentWatch entry for US 6,315,720 (absent, linked) — https://www.drugpatentwatch.com/p/patent/[6315720](/patent/6315720).

I'll ground this analysis in the prior-art reference list on the patent page, cross-checking the two closest references (the Celgene restricted-distribution patents) since the fetched text gives me only titles and dates for the cited art.

Obviousness Analysis — U.S. Patent No. 7,895,059 under 35 U.S.C. § 103

Analysis date: April 26, 2026 (note: the page's fetch stamp reads 2026‑10‑01; the discrepancy doesn't affect the analysis).

0. Scope, evidence base, and caveats (read first)

1. What I am working from. Per the task, I rely on the Prior Art section of the patent page — the "Citations (43)" list. The fetched page renders only 12 of those 43 entries (the twelfth, US 6,315,720, is truncated mid‑row). The remaining ~31 references are not visible to me, so my combination analysis necessarily under‑uses the full record. Where I rely on my own knowledge of a reference's disclosure beyond its title, I say so.

2. The historically operative § 103 ground was NOT these patent citations. The '059 claims were cancelled in IPR2015‑00548 (FWD July 27, 2016) as obvious over FDA Advisory Committee ("ACA") materials, and that holding was affirmed in Jazz Pharmaceuticals, Inc. v. [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC), 895 F.3d 1347 (Fed. Cir. July 13, 2018). The ACA materials are non‑patent literature and do not appear in the page's "Citations" list. Any complete obviousness picture must therefore include them. I treat them separately in § 5 because they are the ground that actually carried the day.

3. This analysis is not a validity opinion. It is a technical, good‑faith reconstruction of how a person having ordinary skill in the art ("POSITA") — a pharmaceutical‑distribution/health‑IT professional with familiarity with FDA risk‑management programs — could have combined the cited art. I flag confidence levels throughout.

1. Legal framework applied

• Graham v. John Deere Co., 383 U.S. 1 (1966): scope/content of the prior art; differences between the claims and the prior art; level of ordinary skill; secondary considerations.
• KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007): a combination is obvious where the improvement is "the predictable use of prior art elements according to their established functions," where there is a "design need or market pressure," or where a "finite number of identified, predictable solutions" exists. Motivation to combine need not be found in the references themselves — it may come from common sense, the nature of the problem, or the background knowledge of the artisan.
• Pre‑AIA § 103 governs (priority date December 17, 2002). The one‑year critical date for printed publications is December 17, 2001 — which is exactly why the ACA materials' October 4, 2001 public accessibility mattered in the IPR.

2. The invention, and where the arguable novelty sits

Sole independent‑claim features common to claims 1, 6, 9, 12, 13, 14 (supra, prior sections):

The whole § 103 fight is about A and B — the "exclusivity" (single‑pharmacy / single‑database) architecture. Everything else (C–J) was squarely in the art by 2001. A defensible obviousness case therefore concentrates on showing that collapsing a multi‑pharmacy registered network into a single exclusive central‑pharmacy/single‑database channel was an obvious design choice.

3. The primary prior art (the "Citations" list)

3.1 The Celgene references — the closest art (high confidence)

Two references on the page are directly on point and are the backbone of any § 103 case:

• US 6,045,501 B1 — Elsayed et al., Celgene Corp., "Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug" (filed 1998‑08‑28; granted 2000‑04‑04).
• US 6,315,720 B1 — Williams et al., Celgene Corp., "Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug" (granted 2001‑11‑13).

Verified disclosures (from the returned record, e.g. https://patents.google.com/patent/[US6315720B1](/patent/US6315720B1) and https://patents.google.com/patent/US6045501):

• Prescriptions are filled "only after a computer readable storage medium has been consulted to assure that the prescriber is registered in the medium and qualified to prescribe the drug, that the pharmacy is registered in the medium and qualified to fill the prescription for the drug, and the patient is registered in the medium and approved to receive the drug." → maps to Element C and provides the central‑registry spine for A/B.
• Registration/verification of prescribers, pharmacies, and patients in the medium, including prescriber qualification → Element C.
• Counseling/educational information provided to patients; reinforcement of prescriber/pharmacy behavior → Element D.
• Risk‑group assignment of patients and entry of that assignment into the medium; retrieval of subpopulations and determination of contraindication before authorization → Elements E/F (a risk‑stratification analogue of "potential abuse" screening).
• Authorizing registered pharmacies to fill prescriptions from registered prescribers for approved patients → the gating/dispensing condition of Element F.
• Explicit statement that the methods provide "means for monitoring, controlling and authorizing the distribution" and that the checks and balances "serve to limit unauthorized and possibly inappropriate distribution." → supplies the motivation for A/B.

The '720 reference expressly builds on the '501 reference ("US Pat. No. 6,045,501 … provides methods for delivering a drug …"), i.e., the two are a self‑identified improvement chain — a powerful, built‑in motivation to combine.

Key gap: both describe a registered pharmacies (plural) network, not a single exclusive pharmacy with a single exclusive database. That gap is the entire remaining § 103 question.

3.2 The general‑purpose computerized prescription / pharmacy‑management art (moderate‑high confidence as to subject matter; I rely on titles + general knowledge)

These references supply the "computer processor / electronic database / order‑generation / reporting" machinery and the automation motivation:

3.3 The tracking / restricted‑clinical‑supply reference

• US 6,055,507 A — Cunningham, "Method and system for dispensing, tracking and managing pharmaceutical trial products" (1996‑12‑09; 2000‑04‑25). This is a single controlled‑distribution channel model for a sensitive (investigational) product, with per‑patient tracking, dispensing records, and accountability. It is the best citation‑list answer to the "single channel" (Element A) gap because it teaches centralizing distribution of a controlled product rather than relying on ordinary retail channels.

3.4 The ACA materials (non‑patent literature; the ground that actually won)

The Oct. 4, 2001 FDA Advisory Committee materials described Orphan Medical's proposed Xyrem® restricted‑distribution program — i.e., a single central pharmacy through which all Xyrem prescriptions would be filled, with prescriber and patient enrollment, education, and monitoring. These materials map onto A/B/C/D/E/F almost element‑for‑element and are the reason the Board found the claims obvious.

4. Element‑by‑element mapping (independent claim 1 as representative)

Result: every limitation except the strict "exclusivity" of A/B is disclosed or plainly suggested in the citation list; A/B is met directly by Cunningham '507 and the ACA materials, and is an obvious design choice over Celgene.

5. The combinations, and the motivation to combine

Combination 1 (baseline): Celgene '501/'720 + a computerized prescription‑management system ('255 or '539 or '182 or '144 or '074)

• Motivation: The '720 reference itself frames the problem — it is an "improvement" of '501 aimed at "minimiz[ing] and simplify[ing] the demands on the pharmacy … improving compliance." Automating a known manual registration/authorization workflow with a general‑purpose prescription‑management computer (Expressly designed for exactly this) is the predictable use of known elements for their established functions (KSR). Both references are in the same field (controlled pharmaceutical distribution) and address the same problem (preventing improper dispensing).
• Reasonably expected to work: Combining a registration/authorization decision tree with an electronic Rx/record system requires only routine programming.
• What it renders obvious: Elements B–H, and largely C–F. Not, by itself, the single‑pharmacy exclusivity of A/B.

Combination 2 (bridges the "single pharmacy" gap): Celgene '501/'720 + Cunningham '507 (optionally + Pyxis '392)

• Motivation: Celgene's stated object is to "limit unauthorized and possibly inappropriate distribution." Cunningham '507 supplies the known technique of routing a sensitive pharmaceutical through a single controlled distribution channel with per‑patient accountability rather than an open retail network. A POSITA confronted with the diversion/abuse problem — and the known downside of multi‑pharmacy networks (more diversion points, uneven compliance) — would foreseeably consolidate to one exclusive pharmacy and one exclusive database to tighten control. KSR supports this: a "design need or market pressure," and a "finite number of identified, predictable solutions."
• Pyxis '392 / Meditrol '764 additionally support the "locked/controlled dispensing + reconciliation" concept that the specification itself invokes ("a locked cabinet or safe is a requirement").
• What it renders obvious: Elements A and B, completing claim 1.

Combination 3 (GHB‑specific claims 9, 12, 13): Combination 2 + ACA materials (and, for claim 13, the vertical‑integration steps)

• Claims 9/12 simply substitute "GHB" for "prescription drug," which the ACA materials do expressly (the Xyrem program), and which the specification concedes is its own working example.
• Claim 12's "mailing or sending by courier" is routine.
• Claim 13 adds "manufacturing GHB" and "providing manufactured GHB only to the exclusive central pharmacy." Limiting a controlled product's supply to a single downstream channel is the ordinary, predictable commercial implementation of the same anti‑diversion goal (and echoes the consignment‑inventory / single‑site‑manufacture model in the specification). Under KSR this is an obvious business/technical integration, not an inventive step.

Combination 4 (the ground that actually prevailed): ACA materials alone, or ACA + Celgene

The ACA materials disclosed the single‑central‑pharmacy Xyrem program with enrollment, education, and monitoring; Celgene supplies the registration/authorization/education architecture. That combination is what the PTAB adopted and the Federal Circuit affirmed.

6. Dependent claims

Dependent claims add little independent weight; each is supported by the cited art:

7. Secondary considerations (Graham factor 4)

Jazz could and did point to real‑world indicia — Xyrem's commercial success, the long‑felt need to distribute an abusable drug safely, and industry copying. Three counterweights:

1. Nexus is the weak link. The commercial success is attributable to the drug/indication and the FDA‑mandated restricted‑distribution requirement, not to the specific "single exclusive pharmacy / single exclusive database" claim architecture. Without a nexus, the secondary evidence is discounted.
2. No teaching away in the record from centralizing distribution; the field's trajectory (thalidomide, isotretinoin, clozapine) was toward tighter, more centralized control.
3. Simultaneous invention / industry adoption of central‑pharmacy REMS‑type programs is itself evidence of obviousness (KSR endorses "the effects of demands known to the design community").

The Federal Circuit's 2018 affirmance confirms that, on this record, the secondary considerations did not overcome the obviousness case.

8. Conclusion

The claims of U.S. 7,895,059 are invalid as obvious under § 103. The strongest, most defensible showings are:

• Primary: Celgene US 6,315,720 in view of US 6,045,501 (same assignee, express self‑improvement relationship, same field, same problem) further in view of a computerized prescription‑management system (US 5,845,255 / 5,737,539 / 6,112,182 / 2001/0001144) — renders obvious elements B–H.
• To reach the exclusivity limitations (A/B): add Cunningham US 6,055,507 (single controlled distribution channel) and/or Pyxis US 6,021,392; motivation supplied by the references' stated anti‑diversion goal plus KSR's "design need / finite predictable solutions."
• GHB‑specific claims 9/12: add the ACA materials.
• Claim 13's manufacturing/sole‑supply steps: obvious vertical integration consistent with the anti‑diversion objective.
• Historically dispositive: the FDA ACA materials (Oct. 4, 2001) alone or with Celgene — the ground the PTAB adopted and the Federal Circuit affirmed (Jazz v. Amneal, 895 F.3d 1347 (Fed. Cir. 2018)), resulting in cancellation of claims 1–16.

Confidence and open items

• High confidence: Celgene '501/'720 disclosures (verified above); the IPR/Federal Circuit invalidity outcome; the "exclusivity of the single pharmacy/database" being the crux.
• Moderate confidence: exact disclosures of the computerization references ('255, '539, '074, '392, '182, '144) — I reasoned from titles plus general knowledge, as the fetched text supplies titles/dates only.
• Explicit gap: the "Citations (43)" list renders only 12 entries; ~31 cited references are not available to me and could strengthen or (less likely) complicate the combinations. The ACA materials are not in the Citations list but are indispensable to the real § 103 posture.
• Flagged contradiction with the already‑generated sections: none on substance. The only discrepancy to note is cosmetic — the header of this task states the current date as April 26, 2026, while the page fetch stamp reads 2026‑10‑01; neither affects the analysis. The prior sections' observation that no 2026 Federal Circuit docket has the '059 patent in suit is consistent with the patent having expired (2022‑12‑17) after its claims were cancelled.

If you'd like, I can attempt to recover the remaining ~31 cited references or pull the IPR2015‑00548 FWD's specific claim chart, which would let me replace my reconstructions with the Board's actual element‑by‑element findings.